Invest in 10,000+ US Stocks and ETFs
* Offering through VF Securities, Inc. (member FINRA/SIPC)
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company offers diagnostic products comprising TRUFORMA Bulk Acoustic Wave point of care diagnostic platform; TRUVIEW, a digital cystoscopy platform that offers automated slide preparation within the instrument; and VetGuardian, a zero-touch vital signs remote monitoring system. It also provides therapeutic products, including PulseVet electrohydraulic shockwave therapy platform; and Assisi Loop line of products, including the Assisi Loop, Assisi Loop Lounge, and DentaLoop devices that treat pain and inflammation through delivery of targeted pulsed electromagnetic field focused energy. The company has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for the development of a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. is headquartered in Ann Arbor, Michigan. more
Time Frame | ZOM | Sector | S&P500 |
---|---|---|---|
1-Week Return | -4.84% | -2.06% | -0.55% |
1-Month Return | -7.09% | -1.92% | 2.72% |
3-Month Return | -7.81% | -10.4% | 7.66% |
6-Month Return | -16.31% | -4.6% | 10.15% |
1-Year Return | -38.86% | 4.06% | 27.53% |
3-Year Return | -66.29% | 1.94% | 32.31% |
5-Year Return | -63.35% | 36.48% | 89.2% |
10-Year Return | -85.77% | 97.46% | 194.59% |
Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | 5YR TREND | |
---|---|---|---|---|---|---|
Total Revenue | - | 14.12K | 4.13M | 18.93M | 25.19M | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":0.06,"profit":true},{"date":"2021-12-31","value":16.41,"profit":true},{"date":"2022-12-31","value":75.16,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Cost of Revenue | 787.61K | 530.02K | 1.08M | 5.28M | 7.87M | [{"date":"2019-12-31","value":10.01,"profit":true},{"date":"2020-12-31","value":6.74,"profit":true},{"date":"2021-12-31","value":13.71,"profit":true},{"date":"2022-12-31","value":67.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Profit | (787.61K) | (530.02K) | 3.05M | 13.65M | 17.32M | [{"date":"2019-12-31","value":-4.55,"profit":false},{"date":"2020-12-31","value":-3.06,"profit":false},{"date":"2021-12-31","value":17.64,"profit":true},{"date":"2022-12-31","value":78.83,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Gross Margin | - | (3752.62%) | 73.89% | 72.12% | 68.76% | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":-5078.48,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":97.6,"profit":true},{"date":"2023-12-31","value":93.05,"profit":true}] |
Operating Expenses | 19.78M | 16.76M | 24.43M | 35.58M | 48.91M | [{"date":"2019-12-31","value":40.45,"profit":true},{"date":"2020-12-31","value":34.28,"profit":true},{"date":"2021-12-31","value":49.94,"profit":true},{"date":"2022-12-31","value":72.74,"profit":true},{"date":"2023-12-31","value":100,"profit":true}] |
Operating Income | (19.78M) | (16.76M) | (21.37M) | (21.92M) | (31.59M) | [{"date":"2019-12-31","value":-1978432700,"profit":false},{"date":"2020-12-31","value":-1676497800,"profit":false},{"date":"2021-12-31","value":-2137399700,"profit":false},{"date":"2022-12-31","value":-2192300000,"profit":false},{"date":"2023-12-31","value":-3159200000,"profit":false}] |
Total Non-Operating Income/Expense | (18.07K) | (114.68K) | 1.01M | 5.24M | 1.17M | [{"date":"2019-12-31","value":-0.34,"profit":false},{"date":"2020-12-31","value":-2.19,"profit":false},{"date":"2021-12-31","value":19.25,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":22.32,"profit":true}] |
Pre-Tax Income | (19.78M) | (16.91M) | (20.72M) | (19.38M) | (35.86M) | [{"date":"2019-12-31","value":-1978405400,"profit":false},{"date":"2020-12-31","value":-1691178400,"profit":false},{"date":"2021-12-31","value":-2071622400,"profit":false},{"date":"2022-12-31","value":-1938100000,"profit":false},{"date":"2023-12-31","value":-3586000000,"profit":false}] |
Income Taxes | 38.08K | 9.33K | (2.33M) | (2.37M) | (1.33M) | [{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":24.51,"profit":true},{"date":"2021-12-31","value":-6127.52,"profit":false},{"date":"2022-12-31","value":-6214.05,"profit":false},{"date":"2023-12-31","value":-3495.73,"profit":false}] |
Income After Taxes | (19.82M) | (16.92M) | (18.38M) | (17.02M) | (34.53M) | [{"date":"2019-12-31","value":-1982212900,"profit":false},{"date":"2020-12-31","value":-1692111700,"profit":false},{"date":"2021-12-31","value":-1838317000,"profit":false},{"date":"2022-12-31","value":-1701500000,"profit":false},{"date":"2023-12-31","value":-3452900000,"profit":false}] |
Income From Continuous Operations | (19.78M) | (16.91M) | (18.38M) | (17.02M) | (14.93M) | [{"date":"2019-12-31","value":-1978405400,"profit":false},{"date":"2020-12-31","value":-1691178400,"profit":false},{"date":"2021-12-31","value":-1838317000,"profit":false},{"date":"2022-12-31","value":-1701500000,"profit":false},{"date":"2023-12-31","value":-1493200000,"profit":false}] |
Income From Discontinued Operations | - | - | - | - | - | [{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}] |
Net Income | (19.82M) | (16.92M) | (18.38M) | (17.02M) | (34.53M) | [{"date":"2019-12-31","value":-1982212900,"profit":false},{"date":"2020-12-31","value":-1692111700,"profit":false},{"date":"2021-12-31","value":-1838317000,"profit":false},{"date":"2022-12-31","value":-1701500000,"profit":false},{"date":"2023-12-31","value":-3452900000,"profit":false}] |
EPS (Diluted) | (0.20) | (0.06) | (0.05) | (0.02) | (0.03) | [{"date":"2019-12-31","value":-20,"profit":false},{"date":"2020-12-31","value":-6,"profit":false},{"date":"2021-12-31","value":-5,"profit":false},{"date":"2022-12-31","value":-2.41,"profit":false},{"date":"2023-12-31","value":-3.1,"profit":false}] |
These ratios help you determine the liquidity of the company. Higher is better.
ZOM | |
---|---|
Cash Ratio | 9.53 |
Current Ratio | 10.82 |
Quick Ratio | 10.15 |
These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.
ZOM | |
---|---|
ROA (LTM) | -9.29% |
ROE (LTM) | -23.92% |
These ratios help you understand the company's liabilities, gauging the riskiness of the investment.
ZOM | |
---|---|
Debt Ratio Lower is generally better. Negative is bad. | 0.05 |
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. | 0.95 |
These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.
ZOM | |
---|---|
Trailing PE | NM |
Forward PE | NM |
P/S (TTM) | 4.56 |
P/B | 0.58 |
Price/FCF | NM |
EV/R | 1.61 |
EV/Ebitda | NM |
Zomedica Pharmaceuticals Corp (ZOM) share price today is $0.118
Yes, Indians can buy shares of Zomedica Pharmaceuticals Corp (ZOM) on Vested. To buy Zomedica Pharmaceuticals Corp from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in ZOM stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.
Yes, you can purchase fractional shares of Zomedica Pharmaceuticals Corp (ZOM) via the Vested app. You can start investing in Zomedica Pharmaceuticals Corp (ZOM) with a minimum investment of $1.
You can invest in shares of Zomedica Pharmaceuticals Corp (ZOM) via Vested in three simple steps:
The 52-week high price of Zomedica Pharmaceuticals Corp (ZOM) is $0.23. The 52-week low price of Zomedica Pharmaceuticals Corp (ZOM) is $0.12.
The price-to-earnings (P/E) ratio of Zomedica Pharmaceuticals Corp (ZOM) is
The price-to-book (P/B) ratio of Zomedica Pharmaceuticals Corp (ZOM) is 0.58
The dividend yield of Zomedica Pharmaceuticals Corp (ZOM) is 0.00%
The market capitalization of Zomedica Pharmaceuticals Corp (ZOM) is $147.60M
The stock symbol (or ticker) of Zomedica Pharmaceuticals Corp is ZOM